NEW ORLEANS & MINNEAPOLIS--(BUSINESS WIRE)--New data presented today at Scientific Sessions 2008 from Medtronic (NYSE: MDT) shows that survival among patients with implantable cardioverter-defibrillators (ICDs) treated only with anti-tachycardia pacing (ATP) was superior to patients who experienced at least one shock-treated episode, further demonstrating the clinical benefit of ATP. Additionally, the analysis evaluating more than 2,000 patients, found no link between inappropriate therapy and mortality, nor a causal relationship between ICD therapy (ATP or shock) and mortality.
